Aditi Shastri, MD
@aditishasMD
Followers
2K
Following
12K
Media
260
Statuses
4K
Assoc Prof, Physician-scientist researching cures for AML & MDS. Addressing health disparities in cancer care. #shastrilab Tweets my own #leusm #mds
New York, NY
Joined June 2017
Kudos to @aditishasMD for organizing our Einstein-Montefiore team at the Move for MDS event this morning in Battery Park and for her inspiring speech! The rain didn’t stop us!
3
3
45
Two 3rd-year med students from my alma mater, Keio Univ (@KeioGlobal, Tokyo), visited Einstein! They had great chats with our lab & @EinsteinMed/@MontefioreNYC colleagues on career paths incl. IMGs & scientists. So inspired by their energy & motivation—their future shines bright!
0
3
15
We are very excited to officially launch our single cell proteomics service!! Please, check out our website if you want to work with us! https://t.co/3beLRHphKU
11
84
509
In our study just published in @BloodCancerJnl Outdoor Air Pollution(OAP) , particularly PM2.5 was associated with a trend towards worse survival in #multiplemyeloma patients treated in a historically redlined area - Bronx, NY. @Einstein_SCI @MontefioreNYC @EinsteinMed
Fine particulate matter exposure is linked to worse myeloma outcomes in a diverse urban cohort | Blood Cancer Journal @aditishasMD
1
11
40
😔 Outdoor air pollution (OAP) was an independent predictor of worsened outcomes in myeloma #MMsm. Elegant epidemiological data from the Bronx (NYC, 🇺🇸 ) by Wysota @aditishasMD et al, but also applicable to patients around the world…
Fine particulate matter exposure is linked to worse myeloma outcomes in a diverse urban cohort | Blood Cancer Journal @aditishasMD
2
2
10
Hi everyone . Please follow #shastrilab on Instagram for latest news and updates from us!
0
0
1
Practice-changing study from @YannisMantz @MontefioreNYC in @BloodJournal adding Ven frontline to globally used AML doublet 3+7 ⬆️ response rates ⬆️application. Happy to be a part of it! #leusm @Einstein_SCI
🔥 Excited for our Phase 1 study Ven + 7+3 for Newly Diagnosed AML demonstrating 85% CR (86% MRD-neg) @BloodJournal @ MontefioreNYC @EinsteinMed @MontefioreNYC Eric J. Feldman @MendelGoldfing2
@mkonople @Amitvermamds @aditishasMD @Gritsman_lab
#leusm
https://t.co/tcGDSCQCFD
1
3
38
Enjoyed a wonderful dinner at City Island with Dr. Peng Ji @PengJi_lab (@NorthwesternU), an @EinsteinPhD alum, Dr. Richard Stanley, and @EinsteinMed colleagues! Thoroughly appreciated Peng’s incredible DMB Liang Zhu Memorial Lecture and the engaging conversations!
1
4
24
It was a great pleasure to co-author this review on recent updates in STAT biology & therapeutics in Myeloid malignancies with @SudhamshDesai Zoe King & David Frank ! @EmoryUniversity @Einstein_SCI @EinsteinMed @MontefioreNYC
Excited to have our work published in Neoplasia! Beyond grateful for the opportunity and mentorship from STAT experts Dr. David Frank and Dr. Aditi Shastri @aditishasMD #MDSsm #AMLsm
https://t.co/3xfo7hWnG3
1
3
19
Thank you 🙏🏼 @doctorpemm for making time to visit @EinsteinMed @MontefioreNYC Da Bronx! For a fantastic talk on #MPN For your friendship & camaraderie always!! We loved having you here and hope you come back! @MDAndersonNews @mkonople @Amitvermamds @Gritsman_lab
1
3
50
Beautiful gift 💝 I received in clinic today! Guess which country ?
1
0
8
It is our great pleasure to host p53 guru Dr. Arnold Levine @Princeton at @EinsteinMed @MontefioreNYC #BCI guest for January 2025! He gave a fabulous talk ! Looking forward to learning a lot from him! @Amitvermamds @The_Will_Lab @Gritsman_lab @Einstein_SCI
0
1
26
Publication alert 👉👉👉 on behalf of the @ic_MDS in @BloodJournal , 'Reducing Clinical Trial Eligibility Barriers for MDS :An icMDS Position Statement'. This paper demonstrates how eligibility criteria for LR & HR MDS often do not vary across trial phases & don't reflect known
8
16
72
Teresa Bowman, Ph.D., received Einstein's inaugural Dr. Fernando Macian-Juan Award for Excellence in Graduate Student Mentoring. The award honors the memory of Dr. Macian-Juan, a professor of pathology for more than 20 years. Learn more at https://t.co/jTwljFgRyY
#MentoringMonth
2
7
56
Had a fantastic visit to @nyulangone yesterday!! Can never pass up the chance to meet old friends @SBKoralov and make several new friends! Thank you very much @iannisaifantis1 @SBKoralov for hosting me ! 🙏🏼 @Einstein_SCI @EinsteinMed
1
0
33
Kicking off 2025 with this outstanding @ic_MDS first online @BloodJournal effort that every clinical researcher, regulator, industry sponsor, reviewer, or anyone involved involved in #MDSsm clinical trials should read before writing or approving an #MDSsm clinical trial protocol
5
17
83
Excited to share our paper on the preclinical efficacy of two novel ALK5 inhibitors, IOA-359 and IOA-360, in stimulating erythroid differentiation in MDS and AML. Grateful to @Amitvermamds and @ Nandini for their support and opportunity! @iOnctura.
1
1
24
Watch for short & sweet #ASH24 Acute Leukemia takeaways for my wonderful community oncology colleagues. 🙏🏽 @OncBrothers for the opportunity and the great work you do !
#ASH24 #Leukemia Highlights w/ @beatalleukemia - #KOMET007 - #CPX351 - #Venetoclax + Induction Full 📢: - https://t.co/wwo9Lfd9pq - https://t.co/uId0JSrSk0 - Also on “Oncology Brothers” podcast #MedTwitter #HemeTwitter #leuksm @TargetedOnc #OncTwitter @ASH_hematology
0
5
22
New 📄🚨on everyone's least favorite myeloid neoplasms:TP53m AML&MDS 🧵In short: 🔴pls don’t exclude these pts of allo-HSCT, their only chance at cure. 🔴TP53 burden is key 🔴Blasts matter (for real… not only b/c I’m a pathologist 🔬😉) https://t.co/ct0EDfRk3O
1
27
124